Merck has invested US$272.69 million for the expansion of its Biotech Development Center in Corsier-sur-Vevey, Switzerland.
The facility located near Merck's current biotech commercial manufacturing site is dedicated to biotech development and manufacturing for clinical studies.
The Development Center will connect research and manufacturing.
This new facility will help the company meet the growing global demand for biotechnology drugs and support its portfolio of biotech medicines.
The new building will be equipped with the most advanced digital solutions and highest technological standards, including continuous manufacturing and laboratory automation.
It will also provide a flexible-by-design infrastructure to readily adapt to emerging needs and technology evolution, as well as open workspaces enabling creativity, collaboration, and innovation.
The Biotech Development Center will display Merck's science and technology across its three business sectors, including Life Sciences process solutions for clinical manufacturing and pilot plant operations, as well as Performance Materials' eyrise® dynamic liquid crystal windows as part of the highly efficient energy management of the building.
The construction of the building is expected to be completed in 2021 and the Development Center is expected to be fully operational by the end of 2022, following approval by regulatory authorities.